Testosterone, HDL and cardiovascular risk in men: the jury is still out.

Testosterone, HDL and cardiovascular risk in men: the jury is still out. Clin Lipidol. 2012 Aug 1;7(4):363-365 Authors: Rubinow KB, Page ST Abstract "Even when reductions in HDL-cholesterol are observed as a consequence of androgen therapy, the implications for cardiovascular risk modification remain highly uncertain." PMID: 25379057 [PubMed - as supplied by publisher]
Source: Clinical Lipidology - Category: Lipidology Tags: Clin Lipidol Source Type: research